Literature DB >> 1347072

Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice.

Y Kataoka1, I Basic, J Perrin, D J Grdina.   

Abstract

The antimutagenic effects of the radiation protective agent, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), were studied against fission-spectrum-neutron- and 60Co-gamma-ray-induced mutagenesis in mice. Mutagenesis at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus was measured 56 days following whole-body irradiation with JANUS neutrons (single doses, 50-150 cGy) or 60Co photons (single doses, 250-750 cGy). Splenic T lymphocytes from B6CF1 mice were grown in round-bottomed 96-microwell culture plates with or without the selective agent 6-thioguanine (6-TG). The mutant frequency, as a result of exposure to neutrons or 60Co photons, increased 100-fold with dose. Doses of 150 cGy neutrons and 750 cGy 60Co photons were equally mutagenic. When animals were injected with WR-2721 at a dose of 400 mg/kg body weight, i.p., 30 min before whole-body irradiation with JANUS neutrons or 60Co photons, mutant frequencies were significantly reduced at all radiation doses (i.e. protection factors of 1.4 and 2.4, respectively). Thus, the aminothiols are effective antimutagens. A novel clinical application of these compounds could be in their use to protect against radiation- and/or chemotherapy-induced genotoxic damage to normal cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347072     DOI: 10.1080/09553009214551081

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  8 in total

1.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

Review 2.  A risk-benefit assessment of amifostine in cytoprotection.

Authors:  M Mabro; S Faivre; E Raymond
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.

Authors:  D J Grdina; J S Murley; J C Roberts
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

5.  WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.

Authors:  Dale M Walker; Adriana E Kajon; Salina M Torres; Meghan M Carter; Consuelo L McCash; James A Swenberg; Patricia B Upton; Andrew W Hardy; Ofelia A Olivero; Gene M Shearer; Miriam C Poirier; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-07       Impact factor: 3.216

Review 6.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

Review 7.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Amifostine protection against mitomycin-induced chromosomal breakage in fanconi anaemia lymphocytes.

Authors:  Ricardo M Camelo; Fernanda S G Kehdy; Carlos E Salas; Miriam T P Lopes
Journal:  Molecules       Date:  2008-08-21       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.